Status:
COMPLETED
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Lead Sponsor:
Tanabe Pharma Corporation
Collaborating Sponsors:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Eligibility Criteria
Inclusion
- Patients diagnosed with genotype 1b chronic hepatitis C
- Patients naive to the concomitant medications with interferon
Exclusion
- Patients diagnosed with decompensated cirrhosis
- Patients diagnosed with positive HBs antigen in the test
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00621296
Start Date
January 1 2008
End Date
February 1 2009
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan